(IN BRIEF) The Institute of Cancer Research, London, has published two major studies demonstrating how pairing a cancer-killing reovirus with targeted therapies such as talazoparib and palbociclib can greatly strengthen immune activity and tumour destruction. By disrupting cancer cell defences … Read the full press release
Posted in Business, Education, Financial, Healthcare, Industrial, Investment, Management, Marketing, News, Science, Technology, United Kingdom
Tagged Cancer Research UK, immune activation, immune checkpoint inhibitors, Joan Kyula-Currie, Kevin Harrington, London, Nature Communications, oncolytic virus, Oncolytics Biotech, Palbociclib, PARP-1, personalised cancer therapies, reovirus, RIG-I, Royal Marsden, talazoparib, The Institute of Cancer Research, tumour stress response, Victoria Roulstone, virotherapy
LONDON, 16-Nov-2017 — /EuropaWire/ — The Institute of Cancer Research, London, welcomes the approval by NICE of a new type of treatment for women with previously untreated advanced breast cancer. Palbociclib and ribociclib, two new drugs approved today for use on the NHS, … Read the full press release
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?